<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01008137</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-PanFlu-4002</org_study_id>
    <nct_id>NCT01008137</nct_id>
  </id_info>
  <brief_title>Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults</brief_title>
  <official_title>Cell-mediated Immunity Study of H1N1 Influenza A Vaccine With Trivalent Inactivated Influenza Vaccine in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <brief_summary>
    <textblock>
      A single center, randomized clinical trial is to be conducted in healthy adults (18-60 years)
      to evaluate the safety and immunogenicity and study the cell-mediated Immunity of Sinovac's
      H1N1 influenza A Vaccine (PANFLU.1) with Trivalent Inactivated Influenza Vaccine (ANFLU).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study the cell-mediated immunity of H1N1 vaccine with seasonal influenza vaccine</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate immunogenicity of H1N1 vaccine with seasonal influenza vaccine in adults</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety of H1N1 vaccine with seasonal influenza vaccine in adults</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1: Day 0-PANFLU.1; Day 21-ANFLU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine; Day 21: 15 μg ANFLU vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Day 0-ANFLU; Day 21-PANFLU.1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 subjects to receive-Day 0: 15 μg ANFLU vaccine; Day 21: 15 μg PANFLU.1 vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Day 0-PANFLU.1+ANFLU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine+ANFLU vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H1N1 influenza A Vaccine (PANFLU.1)</intervention_name>
    <description>H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)</description>
    <arm_group_label>Group 1: Day 0-PANFLU.1; Day 21-ANFLU</arm_group_label>
    <arm_group_label>Group 2: Day 0-ANFLU; Day 21-PANFLU.1</arm_group_label>
    <arm_group_label>Group 3: Day 0-PANFLU.1+ANFLU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent Inactivated Influenza Vaccine (ANFLU)</intervention_name>
    <description>Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)</description>
    <arm_group_label>Group 1: Day 0-PANFLU.1; Day 21-ANFLU</arm_group_label>
    <arm_group_label>Group 2: Day 0-ANFLU; Day 21-PANFLU.1</arm_group_label>
    <arm_group_label>Group 3: Day 0-PANFLU.1+ANFLU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female aged between 18 and 60

          2. Be able to show legal identity card for the sake of recruitment

          3. Volunteers are able to understand and sign the informed consent

        Exclusion Criteria:

          1. Cases, cured cases and close contact of influenza A (H1N1) virus

          2. History of H1N1 vaccine or seasonal influenza vaccine administration

          3. Women of pregnancy, lactation or about to be pregnant in 60 days

          4. Subject that has a medical history of any of the following: allergic history, or
             allergic to any ingredient of vaccine, such as egg, egg protein, etc

          5. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory
             difficulty, angioedema, or abdominal pain

          6. Autoimmune disease or immunodeficiency

          7. Asthma that is unstable or required emergent care, hospitalization or intubation
             during the past two years or that required the use of oral or intravenous
             corticosteroids

          8. Diabetes mellitus (type I or II), with the exception of gestational diabetes

          9. History of thyroidectomy or thyroid disease that required medication within the past
             12 months

         10. Serious angioedema episodes within the previous 3 years or requiring medication in the
             previous two years

         11. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or
             platelet disorder requiring special precautions) or significant bruising or bleeding
             difficulties with IM injections or blood draws

         12. Active malignancy or treated malignancy for which there is not reasonable assurance of
             sustained cure or malignancy that is likely to recur during the period of study

         13. Seizure disorder other than:

               -  Febrile seizures under the age of two years old

               -  Seizures secondary to alcohol withdrawal more than 3 years ago, or

               -  A singular seizure not requiring treatment within the last 3 years

         14. Asplenia, functional asplenia or any condition resulting in the absence or removal o
             the spleen

         15. Guillain-Barre Syndrome

         16. Any history of immunosuppressive medications or cytotoxic medications or inhaled
             corticosteroids within the past six months (with the exception of corticosteroid nasal
             spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated
             dermatitis)

         17. History of any blood products within 3 months before the dosing

         18. Administration of any other investigational research agents within 30 days before the
             dosing

         19. Administration of any live attenuated vaccine within 30 days before the dosing

         20. Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or
             allergy treatment with antigen injections, within 14 days before the dosing

         21. Be receiving anti-TB prophylaxis or therapy currently

         22. Axillary temperature &gt; 37.0 centigrade at the time of dosing

         23. Psychiatric condition that precludes compliance with the protocol:

               -  Past or present psychoses

               -  Past or present bipolar disorder requiring therapy that has not been well
                  controlled on medication for the past two years

               -  Disorder requiring lithium

               -  Suicidal ideation occurring within five years prior to enrollment

         24. Any medical, psychiatric, social condition, occupational reason or other
             responsibility that, in the judgment of the investigator, is a contraindication to
             protocol participation or impairs a volunteer's ability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Centers for Diseases Control and Prevention</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2009</study_first_submitted>
  <study_first_submitted_qc>November 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2009</study_first_posted>
  <last_update_submitted>November 26, 2012</last_update_submitted>
  <last_update_submitted_qc>November 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

